Semax + Selank Blend Spray is a research-use-only peptide preparation combining two synthetic heptapeptides, Semax and Selank, for controlled laboratory and scientific investigation. Semax is structurally related to the ACTH(4–10) peptide fragment, while Selank is a synthetic analogue of the endogenous peptide tuftsin. The combination is relevant to research involving peptide structure, molecular signaling, neurobiology, receptor interactions, enzymatic activity, and related biochemical pathways. Helix Bio supplies research materials for laboratory use only. This product is not intended for human or veterinary administration.
HPLC certified
Independent analysis
Highest standard
Full traceability
Semax and Selank are distinct synthetic peptides that have appeared in scientific literature examining molecular, biochemical, and neurobiological processes.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro and is structurally associated with the N-terminal fragment of adrenocorticotropic hormone (ACTH). Research has examined Semax in models involving neurobiology, peptide-receptor interactions, gene expression, and neurotrophic signaling.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro and is an analogue of tuftsin. Published research has investigated Selank in relation to peptide metabolism, receptor-associated signaling, gene expression, and biochemical pathways.
The Semax + Selank Blend Spray brings these two research compounds together in one prepared format. The blend is intended to provide researchers with a defined material for laboratory investigation where both peptide sequences are relevant to the experimental design.
The product contains two peptide components:
The exact concentration, formulation, and lot-specific analytical characteristics should be confirmed against the current product documentation and Certificate of Analysis before use in an experiment.
The Semax + Selank combination may be relevant to laboratory research examining:
The presence of two distinct peptide molecules makes the blend particularly relevant to studies designed to examine combined or comparative peptide behavior. Experimental interpretation should account for the individual properties of each component rather than treating the blend as a single molecular entity.
A peptide blend can be useful when an experimental workflow calls for more than one defined peptide component in the same research material.
Semax + Selank Blend Spray provides researchers with a prepared combination of two well-characterized synthetic heptapeptides that have been investigated independently in the scientific literature. This can support research designs focused on comparative peptide biology, molecular interactions, or pathways where both compounds are relevant.
For analytical work, documentation is especially important. Researchers should verify the lot number, reported purity, molecular identity, formulation, and other product-specific information before incorporating a research material into an experimental protocol.
Helix Bio states that its research products are supported by batch-specific Certificates of Analysis and independent HPLC and mass-spectrometry testing.
Semax + Selank Blend Spray is intended for qualified users conducting legitimate laboratory or scientific research, including:
It is not intended for consumers seeking products for personal use, self-experimentation, diagnosis, prevention, or treatment.
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Cyclic peptides resist protease degradation and reach undruggable targets. Learn how peptide cyclization works and why stability improves. Explore the research.
How continuous flow, automation, enzymatic routes and AI are changing peptide synthesis technology, and what it means for research peptide purity and supply.
AI now designs peptides from scratch. How AlphaFold 3, RFdiffusion and protein language models reshaped peptide discovery in 2026 — research use only.
